Compare AbCellera Biologics Inc (ABCL) vs Newmont Corporation (NEM) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Newmont Corporation (NEM) trades at $95.06, down 2.04% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $2.90 versus $2.07 expected, revenue growth to $22.67 billion in 2025, and robust cash flow of $10.33 billion from operations. Analyst consensus is bullish with a $144.00 price target and 75% buy ratings, though recent gold price volatility has pressured shares.

The outlook remains positive due to low valuation multiples (P/E 12.74, EV/EBITDA 6.27) and record free cash flow, but risks include gold market fluctuations and execution of expansion projects. The stock presents a value opportunity for long-term investors, supported by a strong balance sheet and dividend payments.